A prospective, multicenter, noninterventional study of decision factors in the first-line treatment of metastatic non-small cell lung cancer

被引：1

作者：

Sibille, Anne ^{[1
]}

Bustin, Frederique ^{[2
]}

Carestia, Luciano ^{[3
]}

Catala, Gaetan ^{[4
]}

Compere, Christophe ^{[5
]}

Cuppens, Kristof ^{[6
]}

Colinet, Benoit ^{[7
]}

Coulon, Stephanie ^{[8
]}

De Brucker, Nele ^{[9
]}

Decoster, Lore ^{[10
]}

Decoster, Lynn ^{[11
]}

Demedts, Ingel ^{[12
]}

Derijcke, Sofie ^{[13
]}

Deschepper, Koen ^{[14
]}

Galdermans, Danny ^{[15
]}

Janssens, Annelies ^{[16
]}

Ocak, Sebahat ^{[17
,18
]}

Oyen, Christel ^{[19
]}

Pat, Karin ^{[6
]}

Pieters, Thierry ^{[20
]}

Pruniau, Vincent ^{[8
]}

Surmont, Veerle ^{[21
]}

Vandekeere, Saar ^{[8
]}

Vansteenkiste, Johan ^{[19
,22
]}

机构：

[1] Univ Hosp Liege, Dept Pulmonol, Liege, Belgium

[2] CHR Citadelle, Dept Pulmonol, Liege, Belgium

[3] Clin Saint Pierre Ottignies, Dept Pulmonol, Ottignies, Belgium

[4] CH Jolimont, Dept Oncol, Haine St Paul, La Louviere, Belgium

[5] CHIREC Hosp, CHIREC Canc Inst, Dept Pulmonol, Brussels, Belgium

[6] Jessa Hosp, Dept Pulmonol & Thorac Oncol, Hasselt, Belgium

[7] Grand Hop Charleroi, Dept Pulmonol, Gilly, Belgium

[8] MSD Belgium, Med Affairs Dept, Brussels, Belgium

[9] Imelda Hosp, Dept Pneumonol, Bonheiden, Belgium

[10] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel UZ Brussel, Dept Med Oncol, Oncologisch Cent, Brussels, Belgium

[11] AZ Turnhout, Dept Pulmonol, Turnhout, Belgium

[12] AZ Delta, Dept Pulm Dis, Roeselare, Belgium

[13] AZ Groeninge, Dept Pulmonol, Kortrijk, Belgium

[14] Algemeen Ziekenhuis Nikolaas, St Niklaas, Belgium

[15] ZNA Middelheim, Dept Pulmonol, Antwerp, Belgium

[16] Antwerp Univ Hosp, MOCA Thorac Oncol, Edegem, Belgium

[17] CHU UCL Namur, Div Pulmonol, Godinne Site, Yvoir, Belgium

[18] Univ Catholique Louvain UCLouvain, Inst Rech Expt & Clin IREC, Pole Pneumol ENT & Dermatol PNEU, Brussels, Belgium

[19] Univ Hosp KU Leuven, Resp Oncol Unit, Leuven, Belgium

[20] Clin Univ St Luc, Dept Pulmonol, Saint Luc, Belgium

[21] Univ Ghent, Dept Resp Med, Ghent, Belgium

[22] Univ Hosp KU Leuven, Resp Oncol Unit, CONTACT Johan Vansteenkiste, Herestr 49, B-3000 Leuven, Belgium

来源：

ACTA ONCOLOGICA | 2022年 / 61卷 / 06期

关键词：

D O I：

10.1080/0284186X.2022.2063700

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：773 / 776

页数：4

共 50 条

[31] Current status of immune-checkpoint inhibitors in the first-line treatment of metastatic non-small cell lung cancer
Tanaka, Kentaro
ANNALS OF ONCOLOGY, 2019, 30 : 32 - 32
[32] FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB AND SOCIETAL COST SAVINGS IN SPAIN
Stanisic, S.
Carpeno, Castro J. D.
Walzer, S.
VALUE IN HEALTH, 2010, 13 (07) : A271 - A271
[33] Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer
Christopoulos, Petros
Harel, Michal
Mcgregor, Kimberly
Brody, Yehuda
Puzanov, Igor
Bar, Jair
Elon, Yehonatan
Sela, Itamar
Yellin, Ben
Lahav, Coren
Raveh, Shani
Reiner-Benaim, Anat
Reinmuth, Niels
Nechushtan, Hovav
Farrugia, David
Bustinza-Linares, Ernesto
Lou, Yanyan
Leibowitz, Raya
Kamer, Iris
Zer Kuch, Alona
Moskovitz, Mor
Levy-Barda, Adva
Koch, Ina
Lotem, Michal
Katzenelson, Rivka
Agbarya, Abed
Price, Gillian
Cheley, Helen
Abu-Amna, Mahmoud
Geldart, Tom
Gottfried, Maya
Tepper, Ella
Polychronis, Andreas
Wolf, Ido
Dicker, Adam P.
Carbone, David P.
Gandara, David R.
JCO PRECISION ONCOLOGY, 2024, 8
[34] Optimal first-line treatment for metastatic ALK plus non-small cell lung cancer-a narrative review
Chazan, Grace
Solomon, Benjamin J.
TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 369 - 378
[35] FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Pai-Scherf, Lee
Blumenthal, Gideon M.
Li, Hongshan
Subramaniam, Sriram
Mishra-Kalyani, Pallavi S.
He, Kun
Zhao, Hong
Yu, Jingyu
Paciga, Mark
Goldberg, Kirsten B.
Mckee, Amy E.
Keegan, Patricia
Pazdur, Richard
ONCOLOGIST, 2017, 22 (11): : 1392 - 1399
[36] Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
Engel-Nitz, Nicole M.
Johnson, Michael P.
Bunner, Scott H.
Ryan, Kellie J.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (06): : 729 - 740
[37] The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer
Kaiqi Zhu
Zhaoyi Pan
Mengyao Qin
Jin Huang
Scientific Reports, 15 (1)
[38] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sotelo, Miguel
Chara, Luis
Riquelme, Alejandro
Toro, Piedad
Lopez, Cynthia
Hernando, Susana
Caviedes, Edinson
Aguayo, Cristina
Bueno, Coralia
Mielgo Rubio, Xabier
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
[39] Bevacizumab in combination with first-line treatment for metastatic non-small cell lung cancer in clinical practice. Results of the EOLE study
Chouaid, C.
Falchero, L.
Schott, R.
Bonnetain, F.
Taguieva-Pioger, N.
Bennouna, J.
REVUE DES MALADIES RESPIRATOIRES, 2017, 34 (01) : 36 - 43
[40] Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study
Zheng, Jing
Cao, He
Li, Yuping
Rao, Chuangzhou
Zhang, Te
Luo, Jiayou
Lv, Dongqing
Zhu, Yanping
Zhou, Jianya
Zhou, Jianying
LUNG CANCER, 2020, 147 : 130 - 136

← 1 2 3 4 5 →